January 2024

NEW YORK, Jan. 8, 2024 /PRNewswire/ — The castration-resistant prostate cancer (CRPC) treatment market is expected to grow by USD 5.98 billion from 2023 to 2028. In addition, the momentum of the market will progress at a CAGR of 8.83% during the forecast period, according to Technavio Rese

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: